How Obesity and Insulin Resistance Raise Cancer Risk

Doctors have long noticed that people with more body fat tend to develop certain cancers more often. For decades, that pattern was treated as a loose statistical trend, the kind of thing correlated with almost everything in modern life. Large studies covering millions of people and multiple cancer types have sharpened the picture considerably. The real question now isn't whether obesity and cancer travel together, but why.

What the Population Data Actually Show

A systematic review combining dozens of long-term studies found that higher body-mass index tracks with higher incidence across several distinct cancers, not just one or two. The pattern held across different populations and study designs, which is part of why researchers, including Andrew Renehan, who led one of the largest of these reviews, treat the association as more than coincidence. A separate global analysis estimated that a meaningful share of cancer cases worldwide can be statistically attributed to high body-mass index. That does not mean every case of these cancers traces back to weight. It means that, across a population, carrying excess body fat shifts the odds measurably upward for some cancer types.

Insulin Resistance: More Than a Blood Sugar Problem

Obesity often comes bundled with insulin resistance, a state where cells stop responding normally to insulin's signal to absorb sugar from the blood. The pancreas compensates by pumping out more insulin, producing hyperinsulinemia, chronically elevated insulin levels circulating in the blood. Insulin resistance is usually discussed as a precursor to type 2 diabetes, but a consensus report from cancer and diabetes researchers concluded it matters for cancer risk on its own, independent of body weight. That distinction matters: someone can carry extra insulin-related risk even if their weight looks unremarkable on a chart.

The Growth Signal Inside the Cell

Insulin is not only a blood-sugar hormone. It also plugs into a cellular growth circuit shared with a closely related hormone called IGF-1, short for insulin-like growth factor-1. Work from researcher Michael Pollak described how insulin and IGF-1 binding to their receptors switches on an internal relay called the PI3K/AKT/mTOR pathway, a chain of signaling proteins that tells a cell to grow, divide, and resist dying. In a healthy cell, this relay turns on after a meal and then turns back down. In a cell that has already picked up cancer-driving mutations, the same signal can act like fuel added to something already smoldering. Consistent with that mechanism, people with higher circulating IGF-1 and lower levels of its binding protein, which normally keeps IGF-1 in check, show increased risk for certain cancers in pooled analyses of blood-based studies.

Fat Tissue as an Active Signaling Organ

It helps to stop thinking of fat as inert storage. Fat tissue releases its own hormone-like messengers, called adipokines, including leptin and adiponectin, and the balance between them shifts as fat accumulates. Expanding fat tissue also recruits immune cells and sustains chronic low-grade inflammation, a persistent, mild immune activity that, over months and years, can reshape the surrounding tissue environment. Researchers reviewing this evidence have argued that this inflammatory environment promotes tumor growth through routes separate from insulin and IGF-1 signaling, even though the two systems likely interact.

Why Breast Cancer After Menopause Stands Out

Among the cancers linked to obesity, postmenopausal breast cancer shows one of the clearer mechanistic stories. After menopause, the ovaries stop producing estrogen, but fat tissue becomes the body's main remaining source of it. More fat tissue means more estrogen production, and estrogen is a growth signal for many breast tumors. This effect appears to compound with elevated insulin and IGF-1 activity, creating overlapping growth pressure on breast tissue. That combination is likely one reason the obesity-breast cancer link looks stronger after menopause than before it, when ovarian estrogen dominates regardless of body fat.

Does Losing Weight Lower Cancer Risk?

If excess fat and the hormones it generates raise risk, does losing weight reverse it? The Swedish Obese Subjects Study, led by Lars Sjöström, followed obese patients for years after bariatric surgery and compared them with similar patients who did not have surgery. The surgery group developed fewer cancers over the follow-up period. That is a real finding, but it comes from a specific, closely monitored surgical population, not from general weight-loss efforts, and it describes a population-level trend rather than a guarantee for any one person. It does not establish that weight loss through diet or lifestyle change alone would produce the same effect, and it should not be read as evidence that weight loss functions as a cancer treatment.

Where the Science Stands

Taken together, this evidence has moved obesity from a vague lifestyle concern into a recognized, modifiable cancer risk factor. Professional oncology organizations, including the American Society of Clinical Oncology, have issued formal statements acknowledging as much. Still, the biology described here is population-level and probabilistic. It describes shifted odds across large groups of people, not a deterministic outcome for any individual, and it does not mean a person's cancer, once diagnosed, was caused by their weight. What remains less settled is how much of the risk traces to insulin and IGF-1 signaling specifically, versus inflammation, versus other factors that travel alongside excess body fat, and untangling those threads is still active work.